Literature DB >> 6710563

Immunity after treatment of human schistosomiasis mansoni. I. Study design, pretreatment observations and the results of treatment.

A E Butterworth, P R Dalton, D W Dunne, M Mugambi, J H Ouma, B A Richardson, T K Siongok, R F Sturrock.   

Abstract

This paper describes the design of a study on immunity to reinfection after treatment of children with Schistosoma mansoni infections, the initial observations on transmission that led to the selection of the study population, the effects of treatment, and the results of immunological tests carried out before and at five weeks after treatment. Iietune village in Machakos District, Kenya, was selected on the basis of high prevalence and intensities of infection in a small preliminary survey, a stable population living in a small area amenable to detailed study, and a lack of previous intervention in the area. Subsequent observations over a pretreatment period of one year confirmed that prevalence and intensities of infection among children attending the local primary school were high. This was associated with extensive contact of members of the community with water-bodies shown to contain large numbers of infected snails. Analysis of pretreatment intensities of infection and water contact patterns in the schoolchildren allowed the selection of 129 children showing a broad scatter between: (a) high intensity, low water contact, and predicted to be non-immune, and (b) low intensity, high water contact, and predicted to be immune. These children were treated with oxamniquine, 30 mg/kg in divided doses. Five weeks after treatment, 70% of children showed apparent complete cure, and the over-all reduction in geometric mean egg output was 98.9%. Since these children represented only a small proportion of the whole community, there was no obvious reduction in transmission, as reflected by snail infection rates, during the following five-month period. Thus, we are in a position to determine whether successfully treated children do or do not become reinfected in a high transmission environment in which it will be possible to make direct estimates of exposure. Immunological tests carried out immediately before treatment were consistent with a pattern of high exposure leading to the early expression of immune responses in most infected children. Eosinophil levels were elevated in 61% of the children, all of whom showed detectable levels of antibodies against adult worm and egg antigens, as measured by ELISA. In addition, all patients showed antibodies capable of mediating eosinophil-dependent killing of schistosomula. At five weeks after treatment, eosinophil counts and anti-adult worm antibody levels had risen, whereas anti-egg antibodies remained grossly unchanged. The wide variation in the levels of responses shown by different individuals will allow us to test whether such responses are associated with resistance to reinfection during the follow-up period.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6710563     DOI: 10.1016/0035-9203(84)90190-1

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  15 in total

Review 1.  Schistosome vaccines.

Authors:  D W Taylor
Journal:  Experientia       Date:  1991-02-15

2.  Previous or ongoing schistosome infections do not compromise the efficacy of the attenuated cercaria vaccine.

Authors:  Thomas M Kariuki; Govert J Van Dam; André M Deelder; Idle O Farah; Dorcas S Yole; R Alan Wilson; Patricia S Coulson
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

3.  T-helper-2 cytokine responses to Sj97 predict resistance to reinfection with Schistosoma japonicum.

Authors:  Tjalling Leenstra; Luz P Acosta; Hai-Wei Wu; Gretchen C Langdon; Julie S Solomon; Daria L Manalo; Li Su; Mario Jiz; Blanca Jarilla; Archie O Pablo; Stephen T McGarvey; Remigio M Olveda; Jennifer F Friedman; Jonathan D Kurtis
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

4.  Genetic control of schistosome infections by the SM1 locus of the 5q31-q33 region is linked to differentiation of type 2 helper T lymphocytes.

Authors:  V Rodrigues; K Piper; P Couissinier-Paris; O Bacelar; H Dessein; A J Dessein
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

5.  Quality control of Kato slide counts for Schistosoma mansoni: a review of 12 years' experience in Kenya.

Authors:  R F Sturrock; J H Ouma; H C Kariuki; F W Thiongo; D K Koech; A E Butterworth
Journal:  Bull World Health Organ       Date:  1997       Impact factor: 9.408

6.  The contribution of water contact behavior to the high Schistosoma mansoni Infection rates observed in the Senegal River Basin.

Authors:  Seydou Sow; Sake J de Vlas; Foekje Stelma; Kim Vereecken; Bruno Gryseels; Katja Polman
Journal:  BMC Infect Dis       Date:  2011-07-18       Impact factor: 3.090

7.  Regulation of primary Strongyloides ratti infections in mice: a role for interleukin-5.

Authors:  K S Ovington; K McKie; K I Matthaei; I G Young; C A Behm
Journal:  Immunology       Date:  1998-11       Impact factor: 7.397

8.  Immunity after treatment of human schistosomiasis: association between cellular responses and resistance to reinfection.

Authors:  M Roberts; A E Butterworth; G Kimani; T Kamau; A J Fulford; D W Dunne; J H Ouma; R F Sturrock
Journal:  Infect Immun       Date:  1993-12       Impact factor: 3.441

9.  Effect of levamisole on the immune response of patients with schistosomiasis after treatment with praziquantel.

Authors:  J R Snyman; de K Sommers
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

10.  T-helper 17 cells are associated with pathology in human schistosomiasis.

Authors:  Moustapha Mbow; Bridget M Larkin; Lynn Meurs; Linda J Wammes; Sanne E de Jong; Lucja A Labuda; Makhtar Camara; Hermelijn H Smits; Katja Polman; Tandakha N Dieye; Souleymane Mboup; Miguel J Stadecker; Maria Yazdanbakhsh
Journal:  J Infect Dis       Date:  2012-10-19       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.